Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 2 news outlets

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 3 news stories from 2 outlets.

Westin Highlights Key Clinical Trial Updates from the 2023 ASCO Annual Meeting in Gynecologic Oncology

OncLive, 18 Jul 2023

Shannon Westin, MD, MPH Results from the phase 3 KEYNOTE-826 trial (NCT03635567), SHAPE trial (NCT01658930), and phase 3…

Dostarlimab Has ‘Impactful’ PFS Benefit in dMMR Advanced Endometrial Cancer

Cancer Network, 28 Jun 2023

Dostarlimab-gxly (Jemperli) is a “powerful addition” to first-line chemotherapy in the treatment of patients with advanced or…

Dostarlimab Earns Priority Review From FDA In Advanced Endometrial Cancer

Cancer Network, 06 Jun 2023

The global, double-blind, multicenter RUBY trial included 494 patients who were randomly assigned to either the dostarlimab (n …

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.